

U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934.

For the quarterly period ended August 31, 2009

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934.

For the transition period from _____ to _____.

Commission File Number 0-12305

REPRO-MED SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

New York 13-3044880
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)

24 Carpenter Road, Chester New York 10918
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (845) 469-2042

(Former name, former address and former fiscal year,
if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and
posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T during the
preceding 12 months (or for such shorter period that the registrant was required
to submit and post such files.) Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of "large accelerated filer," "accelerated filer" and "smaller
reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes No

As of August 31, 2009, 35,584,286 shares of common stock, \$.01 par value per
share, were outstanding.

REPRO-MED SYSTEMS, INC.
TABLE OF CONTENTS

PAGE

PART I FINANCIAL INFORMATION

ITEM 1. Financial Statements

Balance Sheets - August 31, 2009 (Unaudited) and February 28, 2009	3
Statements of Operations (Unaudited) - for the Three-Months and Six months Ended August 31, 2009 and August 31, 2008	4
Statements of Cash Flows (Unaudited) - for the Six-Months Ended August 31, 2009 and August 31, 2008	5
Notes to Financial Statements	6-13

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	14
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk	20
ITEM 4. Controls and Procedures	20
PART II OTHER INFORMATION	

ITEM 1. Legal Proceedings	21
ITEM 1A. Risk Factors	21
ITEM 2. Changes in Securities and Use of Proceeds	21
ITEM 3. Defaults Upon Senior Securities	21
ITEM 4. Submission of Matters to a Vote of Security Holders	21
ITEM 5. Other Information	21
ITEM 6. Exhibits	21

Page 2

PART 1 - FINANCIAL INFORMATION

<TABLE>

REPRO-MED SYSTEMS, INC.
BALANCE SHEETS

<CAPTION>

AUGUST 31, 2009 FEBRUARY 28, 2009

UNAUDITED

<S>

<C> <C>

ASSETS

CURRENT ASSETS:

Cash	\$ 497,604	\$ 519,209	
Accounts receivable less allowance for doubtful accounts of \$28,723 and \$26,783 for August 31, 2009 and February 28, 2009 respectively	478,942	488,742	
Inventory	707,884	621,849	
Prepaid expenses	107,918	73,197	
Deferred Tax Asset Net of Valuation Allowance of \$383,520 and \$383,520 for August 2009 and February 2009 respectively	220,195	306,000	
Total Current Assets	2,012,543	2,008,997	

PROPERTY & EQUIPMENT, less accumulated depreciation of \$1,229,351 and \$1,197,359 at August 31, 2009 and February 28, 2009 respectively	226,884	228,312
--	---------	---------

OTHER ASSETS:

Patents, net of accumulated amortization of \$93,858 and \$91,198 at August 31, 2009 and February 28, 2009, respectively	35,220	36,335
Goodwill	8,609	8,609
Security deposit	28,156	28,156
Total Other Assets	71,985	73,100
TOTAL ASSETS	\$ 2,311,412	\$ 2,310,409

=====

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES

Note payable - current portion	\$ 4,755	\$ 4,600
Notes payable to related parties - current portion	35,661	117,660
Deferred capital gain - current portion	22,481	22,481
Accounts payable	134,776	219,477
Accrued expenses	72,009	142,541
Accrued interest	53,060	46,183
Accrued preferred stock dividends	64,000	60,000
Accrued payroll and related taxes	14,776	13,783
Warranty liability	75,556	93,447
Customer Deposits	62	92
	-----	-----
Total Current Liabilities	477,136	720,264
	-----	-----

OTHER LIABILITIES

Note payable - less current portion	25,285	27,719
Notes payable to related parties - less current portion	639,782	655,003
Deferred capital gain less current portion	191,095	202,335
	-----	-----
Total Other Liabilities	856,162	885,057
	-----	-----
Total Liabilities	1,333,298	1,605,321
	-----	-----

STOCKHOLDERS' EQUITY

Preferred Stock, 8% cumulative, liquidation value \$100,000, \$0.01 par value, 2,000,000 shares authorized, 10,000 shares issued and outstanding at August 31, 2009 and February 28, 2009, respectively	100	100
Common Stock, \$0.01 par value, 50,000,000 shares authorized, 35,584,286 and 34,829,286 issued and outstanding at August 31, 2009 and February 28, 2009, respectively	355,843	348,293
Additional paid-in Capital	3,008,162	2,913,350
Accumulated deficit	(2,243,991)	(2,414,655)
	-----	-----
	1,120,114	847,088
Less: Treasury Stock, 2,275,000 shares at cost at August 31, 2009 and February 28, 2009	(142,000)	(142,000)
	-----	-----
Total Stockholders' Equity	978,114	705,088
	-----	-----
Total Liabilities and Stockholders' Equity	\$ 2,311,412	\$ 2,310,409
	=====	=====

The accompanying notes are an integral part of these Financial Statements

Page 3

</TABLE>

<TABLE>

REPRO-MED SYSTEMS, INC.
STATEMENTS OF OPERATIONS UNAUDITED

<CAPTION>

	FOR THE THREE MONTHS ENDED		FOR THE SIX MONTHS ENDED	
	AUGUST 31,		AUGUST 31,	
	2009	2008	2009	2008
	-----	-----	-----	-----
<S>	<C>	<C>	<C>	<C>
NET SALES	\$ 947,056	\$ 936,495	\$ 1,760,185	\$ 1,636,471
COST AND EXPENSES				
Cost of goods sold	305,681	317,815	618,216	608,935
Selling, general and administrative	424,548	291,729	801,237	602,882
Research and development	6,880	6,728	14,009	10,033
Depreciation and amortization	16,698	22,440	34,652	40,596
	-----	-----	-----	-----
TOTAL COSTS AND EXPENSES	753,807	638,712	1,468,114	1,262,446
	-----	-----	-----	-----
NET OPERATING PROFIT	193,249	297,783	292,071	374,025

OTHER INCOME/(EXPENSES)					
Gain (Loss) Currency Exchange	(2,027)	-	(2,828)	-	
Interest Expense	(11,894)	(18,262)	(24,141)	(29,866)	
Interest and Other Income	442	8	680	8	
	-----	-----	-----	-----	
TOTAL OTHER INCOME/(EXPENSE)	(13,479)	(18,254)	(26,289)	(29,858)	
	-----	-----	-----	-----	
NET PROFIT BEFORE TAXES	179,770	279,529	265,782	344,167	
Provision for Income Taxes	(69,159)	-	(91,118)	-	
	-----	-----	-----	-----	
NET INCOME	\$ 110,611	\$ 279,529	\$ 174,664	\$ 344,167	
PREFERRED STOCK DIVIDENDS	\$ 4,000	4,000	4,000	4,000	
	-----	-----	-----	-----	
NET INCOME AVAILABLE TO COMMON STOCKHOLDERS	\$ 106,611	\$ 275,529	\$ 170,664	\$ 340,167	
	-----	-----	-----	-----	
NET INCOME PER COMMON SHARE AVAILABLE TO COMMON STOCKHOLDERS, BASIC AND DILUTED ..		-	0.01	-	0.01
	=====	=====	=====	=====	=====
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING		35,518,634	34,829,286	35,173,960	34,829,286
	=====	=====	=====	=====	=====

The accompanying notes are an integral part of these Financial Statements

Page 4

</TABLE>

<TABLE>

REPRO-MED SYSTEMS, INC
STATEMENTS OF CASH FLOWS UNAUDITED

<CAPTION>

FOR THE SIX MONTHS ENDED

AUGUST 31, AUGUST 31,
2009 2008

<S>

<C>

<C>

CASH FLOWS FROM OPERATING ACTIVITIES

Net Income	\$ 174,664	\$ 344,167	
Adjustments to reconcile net income to net cash from operating activities:			
Stock based Compensation	19,312	24,209	
Interest charged to additional paid in capital	-	8,820	
Depreciation and amortization	34,652	40,596	
Deferred capital gain - building lease	(11,240)	(11,240)	
Changes in operating assets and liabilities:			
(Increase) decrease in accounts receivable	9,800	(114,048)	
(Increase) decrease in inventory	(86,035)	(12,741)	
(Increase) decrease in prepaid expense	(34,721)	(31,658)	
(Increase) decrease in deferred tax asset	85,805	-	
Increase (decrease) in accounts payable	(84,701)	(193,757)	
Increase (decrease) in accrued payroll and related taxes ...	993	(7,553)	
Increase (decrease) in accrued expense	(70,532)	17,999	
Increase (decrease) in customer deposits	(30)	(5,180)	
Increase (decrease) in warranty liability	(17,891)	-	
Increase (decrease) in accrued interest	6,877	4,600	
	-----	-----	
NET CASH PROVIDED BY OPERATING ACTIVITIES	26,953	64,214	
	-----	-----	

CASH FLOWS FROM INVESTING ACTIVITIES

Payments for property and equipment	(30,564)	-	
Reduction in patents	-	516	
Payments for patents	(1,545)	(680)	
	-----	-----	
NET CASH USED IN INVESTING ACTIVITIES	(32,109)	(164)	
	-----	-----	

CASH FLOWS FROM FINANCING ACTIVITIES

Net payments on note payable to financial institutes	-	(5,733)	
Payments to note payable to related parties	(14,170)	-	
Payments on notes payable	(2,279)	(2,024)	
	-----	-----	
NET CASH USED BY FINANCING ACTIVITIES	(16,449)	(7,757)	
	-----	-----	
NET (DECREASE), INCREASE IN CASH AND CASH EQUIVALENTS	(21,605)	56,293	
CASH BEGINNING OF YEAR	519,209	95,561	
	-----	-----	
CASH END OF YEAR	\$ 497,604	\$ 151,854	
	=====	=====	

Supplemental Information

Cash paid during the year for:

Interest \$ 7,018 \$ 8,209

Non-Cash Activities

Issuance of Common Stock to reduce related party loan \$ 83,050 \$ -

The accompanying notes are an integral part of these Financial Statements

Page 5

</TABLE>

REPRO-MED SYSTEMS, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

NOTE 1 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

THE NATURE OF OPERATIONS

Repro-Med Systems, Inc. (the "Company") was incorporated on March 24, 1980 under the laws of the State of New York. The Company was organized to engage in research, development, laboratory and clinical testing, production and marketing of medical devices used in the treatment of the human condition.

BASIS OF PRESENTATION

The accompanying unaudited financial statements as of August 31, 2009 have been prepared in accordance with generally accepted accounting principles in accordance with instructions to regulation S-X. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial presentation.

In the opinion of the Company's management, the financial statements contain all adjustments (consisting of normal recurring accruals) necessary to present fairly the Company's financial position as of August 31, 2009 and the results of operations and cash flow for the interim periods ended August 31, 2009 and 2008.

The results of operations for the three and six-month periods ended August 31, 2009, are not necessarily indicative of the results to be expected for the full year. These interim financial statements should be read in conjunction with the financial statements and notes thereto of the Company and management's discussion and analysis of financial condition and results of operations included in the Company's Annual Report for the year ended February 28, 2009, as filed with the Securities and Exchange Commission on Form 10-K.

CASH AND CASH EQUIVALENTS

For purposes of the statement of cash flows, the Company considers all short-term investments with an original maturity of three months or less to be cash equivalents.

INVENTORY

Inventories consist of purchased parts and assembled units and are

stated at the lower of average cost or market value. Average cost is calculated using a rolling average based upon new purchases and quantities.

PATENTS

Costs incurred in obtaining patents have been capitalized and are being amortized over seventeen years.

Page 6

REPRO-MED SYSTEMS, INC. NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

INCOME TAXES

Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.

The Company recorded deferred tax assets in the amount of \$603,715 and \$689,520 for the periods ended August 31, 2009 and February 28, 2009, respectively. The deferred tax assets have been offset by valuation allowances of \$383,520 for the periods ended August 31, 2009 and February 28, 2009. Management based the valuation allowance calculations on the prospect of future profitability.

The company recorded a net amount of \$306,000 in available net operating loss tax benefits during the quarter ended February 28, 2009. There were no income tax expense recognized in the three and six-months ended August 31, 2008. For the three and six-months ended August 31, 2009, \$18,245 and \$67,560 were recognized related to the use of a portion of these benefits for current taxable income.

The Company adopted the provisions of FIN 48, Accounting for Uncertainty in Income Taxes, on March 1, 2007. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company does not have any unrecognized tax benefits at August 31, 2009 and February 28, 2009 or during the periods then ended. No unrecognized tax benefits are expected to arise within the next twelve months.

Page 7

REPRO-MED SYSTEMS, INC. NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

PROPERTY AND EQUIPMENT AND DEPRECIATION

Property and equipment is stated at cost and is depreciated using the

straight-line method over the estimated useful lives of the respective assets. Routine maintenance, repairs and replacement costs are expensed as incurred and improvements that extend the useful life of the assets are capitalized. When property and equipment are sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is recognized in operations.

NET INCOME PER COMMON SHARE

Basic earnings per share is computed on the weighted average of common shares outstanding during each year, as prescribed in Statement of Financial Accounting Standards No. 128, Earnings Per Share (SFAS 128). Diluted earnings per share includes an increase to income for the preferred stock dividends and an increase in the weighted average shares by the common shares issuable upon exercise of employee and director stock options (Note 6) and convertible preferred stock shares as follows:

	INCOME	SHARES	PRE-SHARE	
THREE-MONTHS ENDED AUGUST 31, 2009	(NUMERATOR)	(DENOMINATOR)		AMOUNT
Basic Net Income Per Common Share				
Income available	\$ 106,611	35,518,634	\$ -	
Preferred stock dividends	4,000	-	-	
Options includable	-	2,777,685	-	
Convertible preferred stock	-	192,307	-	
Diluted Net Income Per Common Share	\$ 110,611	38,488,626	\$ -	

	INCOME	SHARES	PRE-SHARE	
THREE-MONTHS ENDED AUGUST 31, 2009	(NUMERATOR)	(DENOMINATOR)		AMOUNT
Basic Net Income Per Common Share				
Income available	\$ 170,664	35,173,960	\$ -	
Preferred stock dividends	4,000	-	-	
Options includable	-	2,777,685	-	
Convertible preferred stock	-	192,307	-	
Diluted Net Income Per Common Share	\$ 174,664	38,143,952	\$ -	

USE OF ESTIMATES IN THE FINANCIAL STATEMENTS

The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Important estimates include but are not limited to, asset lives, valuation allowances, inventory and accruals.

REPRO-MED SYSTEMS, INC. NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

ALLOWANCE FOR DOUBTFUL ACCOUNTS

In determining the allowance for doubtful accounts the Company analyzes the aging of accounts receivable, historical bad debts, customer creditworthiness and current economic trends.

REVENUE RECOGNITION

In accordance with Securities and Exchange Commission's (SEC's), Staff Accounting Bulletin No. 104, sales of manufactured products are recorded when shipment occurs and title passes to a customer, persuasive evidence of an arrangement exists with the customer, the sales price is fixed and determinable and the collectability of the sales price is reasonably assured. The Company's revenue stream is derived from the sale of an assembled product. Other service revenues

are recorded as the service is performed. Shipping and handling costs are generally billed to customers and are included in sales. The Company does not accept return of goods shipped unless it is a Company error. The Company does not grant sales allowances other than an occasional 1% discount for payments made within 30 days. The only credits provided to customers are for defective merchandise and sales incentives are occasional advertising in customer catalogues.

STOCK-BASED COMPENSATION

The Company accounts for employee stock based compensation and stock issued for services using the fair value method. In accordance with SFAS No. 123R, the measurement date of shares issued for services is the date when the counterparty's performance is complete.

The Company accounts for stock issued for services using the fair value method. In accordance with the Emerging Issues Task Force ("EITF") 96-18, the measurement date of shares issued for service is the date when the counterparty's performance is complete.

RECLASSIFICATIONS

Certain amounts in the February 28, 2009 and August 31, 2008, financial statements have been reclassified to conform to the presentation used in the August 31, 2009, financial statements.

NOTE 2 INVENTORY

Inventory is valued at the lower of average cost or market and consists of the following at:

	August 31, 2009	February 28, 2009
	-----	-----
Raw materials	\$412,020	\$470,426
Work in progress	24,047	37,391
Finished goods	271,817	114,032
	-----	-----
	\$707,884	\$621,849
	-----	-----

Page 9

REPRO-MED SYSTEMS, INC. NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

NOTE 3 PROPERTY AND EQUIPMENT

Property and equipment consists of the following at:

	August 31, 2009	February 28, 2009	Estimated Useful Lives
	-----	-----	
Furniture and office equipment	\$ 485,757	\$ 459,840	5 years
Manufacturing equipment and tooling .	970,478	965,831	7-12 years
	-----	-----	
	1,456,235	1,425,671	
Less: accumulated amortization and depreciation	1,229,351	1,197,359	
	-----	-----	
Property and Equipment, Net	\$ 226,884	\$ 228,312	
	-----	-----	

Depreciation expense was \$15,289 and \$17,485 for the three months ended August 31, 2009 and August 31, 2008, respectively. Depreciation expense was \$31,992 and \$34,443 for the six months ended August 31, 2009 and August 31, 2008 respectively.

NOTE 4 RELATED PARTY TRANSACTIONS

NOTES PAYABLE TO RELATED PARTIES

The President of the Company has advanced the Company \$100,000 under a

demand loan which bears interest at the rate of 8% (see Note 5 - Long-term debt). This note has been approved by the Board of Directors. The President has agreed to extend the maturity date to March 31, 2011.

LEASED AIRCRAFT

The Company leases an aircraft from a Company controlled by the President. The lease payments aggregated were \$5,375 for the three months ended August 31, 2009 and August 31, 2008, and \$10,750 for six months ended August 31,2009 and August 31,2008. The original lease agreement has expired and the Company is currently on a month-to-month basis for rental payments.

REPRO-MED SYSTEMS, INC.
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

NOTE 5 LONG-TERM DEBT

Long-term debt consists of the following at:

	August 31, 2009	February 28, 2009
	-----	-----
The President of the Company has loaned the Company, \$100,000 at 8% interest. The loan is unsecured and matures March 31, 2011	\$100,000	\$100,000
In January 2008, the Company entered into an installment loan arrangement to purchase a vehicle. The loan bears interest at the rate of 6.735% and is payable in 84 monthly installments of \$552. The loan is secured by the vehicle	30,040	32,319
In February 2009, the Company refinanced a previous loan borrowed from a Director of the Company. The existing loan was replaced by a new \$672,663 loan, payable in monthly installments of \$5,754 at a rate of 6.00% interest. The additional monies financed through the Director were used to pay-off a \$400,000 financial institution note. During the second quarter of 2009, the Company issued the Director 755,000 shares of common stock at the price of \$0.11 per share to further reduce the debt	575,443	672,663
	-----	-----
	705,483	804,982
Less current portion	40,416	122,260
	-----	-----
Long-term portion	\$665,067	\$682,722
	-----	-----

Aggregate maturities as required on long-term debt at August 31, 2009 are:

2010	\$ 40,416
2011	142,915
2012	45,638
2013	48,534
2014	51,615
Thereafter	376,365

	\$705,483

REPRO-MED SYSTEMS, INC.
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

NOTE 6 STOCK OPTIONS

On June 6, 2007, the Board of Directors approved the issuance of 4,360,000 stock options to key employees and directors of the Company. The options have an expiration date of 5 years from the date of grant and an exercise price of \$0.06 per share. Of the 4,360,000 stock options granted, 1,690,000 vested immediately and 890,000 stock options vest each succeeding year for three consecutive years.

The fair value of each option grant was calculated to be \$.0272 on the date of grant using the Black-Schole Option pricing model with the following assumption used for grants during the applicable period.

Risk free rate .. 2.4%
 Volatility 96.16%
 Expected life ... 1.5 years
 Dividend yield .. 0%

During the six-months ended August 31, 2009, \$19,312 in option expense was recorded because the Company records the expense semi-annually from the grant date. As of August 31, 2009, there was approximately \$20,000 of total unrecognized compensation cost related to unvested options. That cost is expected to be recognized within the next year.

The following table summarizes the Company's stock options:

OPTIONS	WEIGHTED-AVERAGE		REMAINING CONTRACTUAL TERM
	WEIGHTED-AVERAGE SHARES	EXERCISE PRICE	
Outstanding at February 28, 2009	3,400,000	0.06	
Granted	-		
Exercised	-		
Forfeited or expired	-		
Outstanding at August 31, 2009 .	3,400,000	0.06	2.8
Exercisable at August 31, 2009 .	2,630,000	0.06	2.8

A summary of the status of the Entity's nonvested shares as of August 31, 2009, and changes during the Six-months ended August 31, 2009, is presented below:

NONVESTED SHARES	WEIGHTED-AVERAGE	
	SHARES	GRANT-DATE FAIR VALUE
Nonvested at February 28, 2009	1,540,000	0.06
Granted	-	
Vested	770,000	0.06
Forfeited	-	
Nonvested at August 31, 2009 .	770,000	0.06

REPRO-MED SYSTEMS, INC.
 NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

NOTE 7 SALE-LEASEBACK TRANSACTION - OPERATING LEASE

On February 25, 1999, the Company entered into a sale-leaseback arrangement whereby the Company sold its land and building at 24 Carpenter Road in Chester, New York and leased it back for a period of 20 years. The leaseback is accounted for as an operating lease. The gain of \$449,617 realized in this transaction has been deferred and is amortized to income in proportion to rental expense over the term of the related lease.

At August 31, 2009 minimum future rental payments are:

Year	Minimum Rental Payments
2010	\$ 132,504

2011	132,504
2012	132,504
2013	132,504
2014	132,504
thereafter ..	596,268

	<u>\$1,258,788</u>

Rent expense aggregated \$33,126 for the three months ended August 31, 2009 and \$30,000 for the three months ended August 31, 2008. Rent expense aggregated \$66,252 for the six months ended August 31, 2009 and \$60,000 for the six months ended August 31, 2008.

NOTE 8 COMMITMENTS AND CONTINGENCIES

Contingencies

The Company is contingently liable to rework and fulfill a contractual commitment of its product for a customer order. The total additional material and labor cost to complete this work approximates \$29,000. The provision has been recorded in the Company's financial statements.

Page 13

PART I ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q contains certain "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) and information relating to us that are based on the beliefs of the management, as well as assumptions made by and information currently available. Our actual results may vary materially from the forward-looking statements made in this report due to important factors such as uncertainties associated with future operating results, unpredictability related to Food and Drug Administration regulations, introduction of competitive products, limited liquidity, reimbursement related risks, government regulation of the home health care industry, success of the research and development effort, market acceptance of Freedom60(R), availability of sufficient capital to continue operations and dependence on key personnel. When used in this report, the words "estimate," "project," "believe," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. Such statements reflect current views with respect to future events based on currently available information and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. These statements involve risks and uncertainties with respect to the ability to raise capital to develop and market new products, acceptance in the market place of new and existing products, ability to penetrate new markets, our success in enforcing and obtaining patents, obtaining required Government approvals and attracting and maintaining key personnel that could cause the actual results to differ materially. Repro-Med does not undertake any obligation to release publicly any revision to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

THREE MONTHS ENDED AUGUST 31, 2009 VS. 2008

Sales of our Freedom60 and related accessories increased 13% for the quarter ended August 31, 2009 over the previous quarter and resulting in total gross sales increasing by 1.5% from \$938,458 to \$952,164 for the three-month period ending August 31, 2009 as compared to the quarter ending August 31, 2008. Returns and allowances were insignificant.

Net profit for the Quarter was \$110,611 as compared to \$279,529 for the same quarter in 2008. Cost of goods sold decreased \$12,134 or 3.8% from \$317,815 in August 31, 2008 to \$305,681 in August 31, 2009. Selling, General and Administrative Expense (SG&A) increased 46% to \$424,548 from \$291,729 quarter

over quarter 2009 vs. 2008, due to increased staffing required for new products. Research and Development increased to \$6,880 from \$6,728 primarily due to reallocation of resources from sales to engineering.

Sales of the Freedom60 Syringe Infusion System, related accessories and repairs increased from \$569,498 to \$644,934, an increase of \$75,436 for the second quarter ending August 31, 2009 as compared to the same period in 2008. This increase is due to the continued increase of sales for use with immune globulin and antibiotics along with word of the costs and performance being communicated throughout the industry. Sales of RES-Q-VAC and related accessories showed an

Page 14

overall decrease of 12% from \$318,983 to \$279,637 due to a general decrease in sales to the emergency markets which we attribute to the general downturn in the economy. Company sales of non-core products increased during the quarter by \$22,233 primarily due to an OEM customer discontinuing one of their product lines. Interest expense decreased by 35% to \$11,894 from \$18,262 for comparative quarter in 2008 as a result of the repayment of certain notes outstanding in 2008.

SIX MONTHS ENDED AUGUST 31, 2009 VS. 2008

Total sales increased by 7.6% (\$123,714) to \$1,760,185 from \$1,636,471 for the six month period ending August 31, 2009.

Net income shows a profit of \$174,664 for the six months ending August 31, 2009 as compared to \$344,167 for the same six months in 2008. Cost of Goods sold increased \$9,281 or 1.5%, from \$608,935 to \$618,216 due to an increase in production payroll and related benefits and production supplies.

Selling, General and Administrative increased from \$602,882 in August 31, 2008 to \$801,237 in August 31, 2009 or 33% resulting from an increase in salaries, benefits and taxes which were added to market our new subcutaneous infusion sets which are still in development. The company also incurred higher auditing fees resulting from obtaining ISO certification status and increases from our SEC auditing and legal fees. In addition the company has hired a full time sales person to focus on the European markets.

Research and Development expenses increased \$3,976, or 40% from 10,033 in 2008 to 14,009 in 2009.

Depreciation and amortization expenses decreased by \$5,944 from \$40,596 in 2008 to \$34,652 in 2009 as a result of assets reaching their fully depreciated values.

LIQUIDITY AND CAPITAL RESOURCES

Net Cash provided from Operations was \$26,953 as compared with net cash provided by operations of \$64,214 for the six months ended August 31, 2008. This decrease is due primarily to a lower net income for the period and payments for fiscal '09 audit fees resulting from a change of auditors and legal fees.

In January of 2008 we were notified by The Trade Adjustment Assistance Program of the Trade Department that our application for a grant of \$150,000 was approved for use to assist us with marketing, ISO and regulatory affairs, and new product development. The grant matches the company on a 50-50 basis thereby reducing our costs for these new programs in half. The Trade Adjustment Assistance Program is a United States Government program to help manufacturing firms adjust to foreign business competition. The program is authorized by the Trade Act of 1974 and is administered by the U. S. Department of Commerce. The program operates through Trade Adjustment Assistance Centers located across the United States. The New York State area is served by the New York State Trade Adjustment Assistance Center (NYS TAAC). The NYS TAAC is affiliated with the Research Foundation of the State University of New York at Binghamton. Minimal funds were used in the previous year however we have initiated these programs now and intend to complete them by the end of our next fiscal year. At the end of August 31, 2009 there is approximately \$55,000 remaining in payment assistance from this grant.

Page 15

We believe the Freedom60 continues to find a solid following in the subcutaneous immune globulin market and this market is expected to continue to increase both domestically and internationally. We continued to experience an increase in sales and cash flow during six months ended August 31, 2009 and with these increases and the capital we currently have, we will continue to meet or exceed the company's financial needs for the next twelve months.

FREEDOM60

The Freedom60 Syringe Infusion Pump is designed for ambulatory medication infusions. Ambulatory infusion pumps are most prevalent in the home care market. Other potential applications for the Freedom60 are pain control, the infusion of specialized drugs such as IgG, and chemotherapy. The home infusion therapy market is comprised of approximately 4,500 sites of service, including local and national organizations, hospital-affiliated organizations, and national home infusion organizations, and produces approximately \$4.5 Billion in revenue annually (Ref: www.nhianet.org). With insurance reimbursement in a severe decline, there is a tremendous need for a low-cost, effective alternative to electronic and expensive disposable IV administration devices for the home care. The Freedom60 provides a high-quality delivery to the patient at costs similar to gravity and is targeted for the home health care industry, patient emergency transportation, and for any time a low-cost infusion is required.

For the home care patient, Freedom60 is an easy-to-use lightweight mechanical pump using a 60cc syringe, completely portable, cost effective and maintenance free, with no batteries to replace and no cumbersome IV pole. For the infusion professional, Freedom60 delivers precise infusion rates and uniform flow profiles providing consistent transfer of medication. A Form 510(k) Pre-market Notification for initial design of the Freedom60 as a Class II device was approved by the FDA in August 1994.

The Company also designed and manufactured the Freedom60-FM, an enhanced version of the Freedom60 which contains an electronic flow monitor system that provides occlusion and end of infusion alarm. This product is directed at nursing homes, hospitals and pediatric ambulatory applications where alarms are generally required for nursing acceptance. Nurses also appreciate being able to visualize the drug volume by reading the scale on the syringe.

We have expanded the use of the Freedom60 to cover most antibiotics including the widely used and somewhat difficult to administer vancomycin. We have also found a following for Freedom60 for use in treating thalissemia with the drug desferal. In Europe we found success in using the Freedom60 for pain control, specifically post-operative epidural pain administration. Our European market also uses the Freedom60 for chemotherapy.

The Freedom60 use for Primary Immune Deficiency by injecting immune globulin (IgG) under the skin as a subcutaneous administration has seen increased usage over the past year. This method has provided patients with vastly improved quality of life with much fewer unpleasant side effects over the traditional intravenous route. The Freedom60 is an ideal system for this administration since the patient is able to self-medicate at home, the pump is easily configured for this application, and the Freedom60 is the lowest cost infusion system available in a heavily cost constrained market. We have begun to advertise one of the main benefits of the Freedom60 for use with IgG which is that it operates in "dynamic equilibrium"; that is the pump finds and maintains a balance between what a patient is able to absorb and what the pump infuses. This balance is created by a safe, limited and controlled pressure which adjusts the flow rate automatically to the patient's needs providing a reliable, faster and a more comfortable administration with fewer side effects for these patients.

Repro-Med Systems' objective is to build a product franchise with Freedom60 and the sale of patented disposable tubing sets. Freedom60 uses rate-controlled tubing with standard slide clamp and luer-lock connector on the patient end. Our patented syringe disc connector insures that only the Company's Freedom60 tubing sets will function with the pump. Non-conforming tubing sets, without the patented disc connector, are ejected from the pump to prevent the danger of an overdose or runaway pump from injuring the patient.

The ambulatory infusion market has been rapidly changing due to reimbursement issues. Insurance reimbursement has drastically reduced the market share of high-end electronic type delivery systems as well as high-cost disposable non-electric devices, providing an opportunity for the Freedom60. We believe market pressures have moved to consider alternatives to expensive electronic systems especially for new subcutaneous administrations which usually cannot be done with gravity. For cost concerns some patients have been trained to administer intravenous drugs through IV push where the drug is pushed into the vein directly from a syringe. This is a low-cost option but has been associated with complications and considered by many to be a high-risk procedure. Thus, the overall trend has been towards syringe pumps due to the low-cost of disposables.

In order to receive more favorable Medicare reimbursement for our Freedom60 Syringe Infusion System, we had submitted a formal request for a HCPCS coding verification with the Statistical Analysis Durable Medical Equipment Regional Carrier (SADMERC). On May 21, 2007 we received a notification from CMS (Centers for Medicare & Medicaid Services) that the Freedom60 had been re-reviewed for Medicare billing. It was the determination that the Medicare HCPCS code(s) to bill the four Durable Medical Regional Carriers (DMERCs) should be: E0779 Ambulatory infusion pump, mechanical, reusable, for infusion 8 hours or greater. The new coding provides for a substantial increase in reimbursement for providers using an infusion pump for authorized users under Part B of Medicare. Current approved uses under Medicare include among others, subcutaneous immune globulin, antivirals, antifungals, and chemotherapeutics.

COMPETITION FOR THE FREEDOM60

Competition for the Freedom60 for IgG is currently limited to electrically powered infusion devices which are more costly and can create high pressures during delivery which can cause complications for the administration of IgG. However, there can be no assurance that other companies with greater resources will not enter the market with competitive products which will have an adverse effect on our sales.

There is the potential for new drugs to enter the market, such as using Hyaluronidase which can facilitate absorption of IgG, making multiple site infusions unnecessary and changing the market conditions for devices such as the Freedom60. We believe the Freedom60 is ideal for all these new drug combinations but there can be no assurance that these newer drugs will have the same needs and requirements as the current drugs being used.

There can be no assurance that Medicare will continue to provide reimbursement for the Freedom60 or they may allow reimbursement for other infusion pumps that are currently in the market or new ones that may enter shortly, which could adversely affect our sales into this market.

Page 17

RES-Q-VAC

The RES-Q-VAC Emergency Airway Suction System is a lightweight, portable, hand-operated suction device that removes fluids from a patient's airway by attaching the RES-Q-VAC pump to various proprietary sterile and non-sterile single-use catheters sized for adult and pediatric suctioning. The one-hand operation makes it extremely effective and the product is generally found in emergency vehicles, hospitals and wherever portable aspiration is a necessity, including backup support for powered suction systems. The disposable features of the RES-Q-VAC reduce the risk of contaminating the health professional from HIV or SARS when suctioning a patient or during post treatment cleanup. All of the parts that connect to the pump are disposable.

We recently introduced a new version of the RES-Q-VAC with the addition of a portable LED white light, which attaches to the canister assembly. The light is fully malleable and can direct light during operations when lighting is poor or at night. We have our latest version of the RES-Q-VAC called Ultra which contains all of our latest enhancements. We have begun marketing the RES-Q-VAC ULTRA both domestically and with a distributor in Italy.

A critical component and advantage of the RES-Q-VAC ULTRA is the Full Stop

Protection, (FSP) a recently patented filtering system that both prevents leakage and over-flow of the aspirated fluids, even at full capacity, and traps all air and fluid borne pathogens and potentially infectious materials within the sealable container. This protects users from potential exposure to disease and contamination. The Full Stop Protection meets the requirement of the Occupational Safety and Health Administration. The Company has received a letter from OSHA confirming that the RES-Q-VAC with the Full Stop Protection falls under the engineering controls of the Blood borne Pathogen regulation and that the Products use would fulfill the regulatory requirements.

We have also added new connectors to our pediatric catheters, which allow them to connect directly to the adult containers with FSP. These connectors allow pediatric suctioning with the benefit of the Full Stop Protection device as well as with sterile catheters. Many infants are born with contagious diseases and the new system eliminates this concern among paramedics during an emergency delivery.

A critical advantage of our RES-Q-VAC airway suction system is versatility. With the addition of Full Stop Protection, we created specific custom RES-Q-VAC kits for various vertical markets:

Emergency Medicine - we make several special kits for emergency use, which contain all the catheters necessary to treat adults as well as infants or children. These first responder kits are generally non-sterile. We also have special attachments available for the advanced paramedic to treat patients who are intubated.

Respiratory - in-home care, long term care, situations requiring frequent suctioning such as cystic fibrosis patients, patients with swallowing disorders, elderly, patients on ventilators and with tracheostomies all benefit from the portability, cost and performance of the RES-Q-VAC. In hospitals, the RES-Q-VAC provides emergency back up due to power loss or breakdown of the wall suction system.

Page 18

Hospital Use - for crash carts, the emergency room, patients in isolation, moving patients throughout the hospital (e.g., from ICU to Radiology) and backup for respiratory, RES-Q-VAC is available sterile with Full Stop Protection for the ultimate in performance and to meet all the OSHA regulations and CDC guidelines for use in treating patients in isolation, and in any location. Hospitals are required under the EMTALA regulations to provide emergency treatments to patients anywhere in the primary facility and up to 250 yards away. The RES-Q-VAC insures full compliance with these regulations and helps minimize unfavorable outcomes and potential lawsuits there from. We provide special hospital kits, which are fully stocked to meet all hospital applications for both adult and pediatric.

Nursing Homes, Hospice, Sub-acute - we provide special configurations for dining areas, portable suctioning for outside events and travel. Chronic suction can be accommodated with RES-Q-VAC, which can be left by the bedside for rapid use during critical times.

Dental Applications - we offer a version of the RES-Q-VAC, called DENTAL-EVAC which addresses the needs of oral surgeons for emergency back up suction during a procedure. DENTAL-EVAC is supplied with the dental suction attachments such as saliva ejector and high volume evacuator.

Military Applications - due to its lightweight, portability, and rapid deployment, we believe that the RES-Q-VAC is ideal for any military situation. In addition, rapid, aggressive, and repeated suctioning best treats exposure to chemical weapons of mass destruction such as Sarin. We believe that the RES-Q-VAC's compact size, powerful pump, and full protection of the user from any contamination, gives us a competitive edge in this market.

RES-Q-VAC is sold domestically and internationally by emergency medical device distributors. These distributors generally sell to the end user and advertise these products in relevant publications and in their catalogs.

COMPETITION FOR THE RES-Q-VAC

Currently there are a number of competitive devices built in China such as Ambu

Res Cue Pump and Easy Breezer, which are essentially copies of the RES-Q-VAC technology, and are available at lower costs. There is also a device called V-Vac made by Laerdal which has strong representation. None of these devices have our patented Full Stop Protection filter, or are available sterile. The RES-Q-VAC currently has greater performance and while lower cost devices initially did affect our sales, currently it appears that we are increasing and maintaining sales in this market. However with the decrease in funding to the emergency medical market due to an economic downturn, there can be no assurance that our sales will continue at the current level, or that these lower cost devices will not begin to erode our markets.

Page 19

TRADE SHOWS

We continue to support both of our main product lines at both National and International tradeshows. In March we exhibited at both the NHIA: National Home Infusion Association's Annual Conference and Exposition and the EMS Today show held in Baltimore, MD. NHIA represents the interests of organizations that provide alternate-site infusion and specialized pharmacy products and services to the entire spectrum of home-based patients, while EMS Today was for the promotion of RES-Q-VAC to the EMS market. In May, we exhibited at INS: Infusion Nurses Society Annual Meeting and Industrial Exhibition in Nashville, TN; the largest meeting for infusion nursing professionals in the United States. In June we traveled to Orlando, FL for the IDF: Immune Deficiency Foundation National Conference which is the largest gathering of patients with primary immunodeficiency diseases in the world. We have also reserved our space for the Medica 2009 trade show to be held in Dusseldorf, Germany this November. Although these shows are primarily for the Freedom60 product line, we are in the process of seeking additional tradeshows for the promotion of RES-Q-VAC. This quarter in May for RES-Q-VAC, we also provided a massive in-service of about 4,000 nurses to a major hospital in Miami, FL.

PART I ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not Applicable

PART I ITEM 4. CONTROLS AND PROCEDURES

The Company's management, including the Company's chief executive officer and chief financial officer, have evaluated the effectiveness of the company's "disclosure controls and procedures "as such is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Based upon their evaluation, the chief executive officer and chief financial officer concluded that, as of the end of the period covered by this report, the Company's disclosure controls and procedures were effective for the purpose of ensuring that the information required to be disclosed in the reports that the Company files or submits under the Exchange Act with the Securities and Exchange Commission (the "SEC") (1) is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and (2) is accumulated and communicated to the Company's management, including its chief executives and chief financial officers, as appropriate to allow timely decisions regarding required disclosure.

There have been no changes in the Company's internal control over financial reporting during the quarter ended August 31, 2009 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Page 20

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are, from time to time, subject to claims and suits arising in the ordinary course of business, including claims for damages for personal injuries, breach of management contracts and employment related claims.

ITEM 1A. RISK FACTORS

Not required for Smaller reporting companies

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matters were submitted to a vote of security holders of the Company during the quarter ended August 31, 2009.

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a) EXHIBITS

31.1 Certification of Chief Executive Officer and Principal Accounting Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002

32.1 Certification of Chief Executive Officer and Principal Accounting Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002

Page 21

SIGNATURES

Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934 the Registrant has duly caused this report to be signed on its behalf by the undersigned; thereunto duly authorized.

REPRO-MED SYSTEMS, INC.

/s/ Andrew I. Sealfon

October 15, 2009

Andrew I. Sealfon, President, Treasurer,
Chairman of the Board, Director, and
Chief Executive Officer

Page 22

EXHIBIT 31.1

CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACTS OF 2002

I, Andrew I. Sealfon, certify that:

- 1) I have reviewed the Form 10-Q of Repro-Med Systems, Inc. (the "Report");
- 2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;
- 4) I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and
- 5) I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.

Date: October 15, 2009

/s/ Andrew I. Sealfon
Andrew I. Sealfon
Chief Executive Officer and Principal Financial Officer

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
SECTIONS 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repro-Med Systems, Inc. (the "Company") on Form 10-Q for the period ending August 31, 2009, as filed with the Securities and Exchange Commission on the date hereof (the Report"), I, Andrew I. Sealfon, Chief Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

- (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results

Date: October 15, 2009

/s/ Andrew I. Sealfon
Andrew I. Sealfon
Chief Executive Officer and Principal Financial Officer